Sold as Wayrilz for other conditions
New approach in eczema
IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity.As this trial registered it · NCT05018806
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness [induration, papulation, edema], scratching [excoriation], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe).As this trial registered it · NCT05018806 (the full definition is there)
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at…As this trial registered it · NCT05018806 (the full definition is there)
rilzabrutinib has one trial with posted results, and NCT05018806 compared the drug with placebo on a result this page charts.
Earliest recorded event: Sep 9, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.